Vascular injury leads to the exposure of blood to fibroblasts and smooth muscle cells within the vessel wall. These cells constitutively express tissue factor (TF), the cellular receptor for plasma clotting factor VIIa (FVIIa). Formation of TF⅐FVIIa complexes on cell surfaces triggers the blood coagulation cascade. In the present study, we have investigated the fate of TF⅐FVIIa complexes formed on the cell surface of fibroblasts in the presence and absence of plasma inhibitor, tissue factor pathway inhibitor (TFPI). FVIIa bound to TF on the cell surface was internalized and degraded without depleting the cell surface TF antigen and activity. TFPI significantly enhanced the TF-specific internalization and degradation of FVIIa. TFPI-enhanced internalization and degradation of FVIIa requires the C-terminal domain of TFPI and factor Xa. TFPI⅐Xa-mediated internalization of FVIIa was associated with the depletion of TF from the cell surface. A majority of the internalized FVIIa was degraded, but a small portion of the internalized FVIIa recycles back to the cell surface as an intact protein. In addition to TF, other cell surface components, such as low density lipoprotein receptor-related protein (LRP) and heparan sulfates, are essential for TFPI⅐Xa-induced internalization of FVIIa. Acidification of cytosol, which selectively inhibits the endocytotic pathway via coated pits, inhibited TFPI⅐Xa-mediated internalization but not the basal internalization of FVIIa. Overall, our data support the concept that FVIIa bound to cell surface TF was endocytosed by two different pathways. FVIIa complexed with TF in the absence of the inhibitor was internalized via a LRP-independent and probably noncoated pit pathway, whereas FVIIa complexed with TF along with the inhibitor was internalized via LRP-dependent coated pit pathway.
Tissue factor (TF) 1 -dependent blood coagulation plays a primary role in hemostasis after tissue injury and also in pathogenesis of many thrombotic disorders associated with a number of diseases, including cardiovascular diseases, sepsis, and cancer (1) . Tissue factor functions as the cellular receptor for plasma clotting factor VIIa (FVIIa) and the formation of TF⅐FVIIa complexes on the cell surface membrane triggers the coagulation cascade (2) . In health, TF is constitutively expressed on the surface membrane of many extravascular cells, such as fibroblasts within blood vessel wall, but not in cells within vasculature that contact blood such as monocytes and endothelial cells (3, 4) . Vessel wall injury disrupts the endothelial cell barrier that normally separates the circulating blood from TF with resultant binding of circulating plasma factor VII to TF sites on cells within the vessel wall and surrounding tissues, such as fibroblasts and pericytes, triggering the coagulation.
TF⅐FVIIa expression on cell surfaces can be regulated by at least three distinct mechanisms: transcriptional regulation of TF gene expression, the availability of anionic phospholipids, and specific plasma inhibitors, particularly tissue factor pathway inhibitor (TFPI) (5) . Besides these, TF⅐FVIIa activity on cell surfaces may also be regulated by other mechanisms. Bach and Moldow (6) proposed that a fraction of TF on cell surfaces exists as dimers that can bind to FVIIa but are unable to activate factor X and that calcium influx into the cytosol triggers a calmodulin-dependent process that causes the dimers to dissociate into monomers capable of factor X activation. It has also been proposed that localization of TF to specialized plasma membrane microdomains, such as caveolae, might limit the function of TF (7, 8) .
Many serine proteases involved in blood coagulation and fibrinolysis bind to cell surface receptors and are subsequently internalized and trafficked within the cells. Such receptormediated endocytosis could also play an important role in regulation of TF-dependent coagulation. However, not much is known about the fate of TF⅐FVIIa complexes assembled on cell surfaces and the role of plasma inhibitors in modulating their fate. Chang and Kisiel (9) reported that FVIIa bound to human hepatoma cell line HuH7 was internalized independent of TF. While our present study was in progress, Hamik et al. (10) reported that TFPI mediated the permanent down-regulation of TF in monocytic cells via low density lipoprotein receptorrelated protein (LRP)-dependent internalization and degradation. In these studies, TFPI-mediated down-regulation of TF was dependent upon the presence of FVIIa but not Xa.
In the present study, we investigated whether binding of FVIIa to TF leads to internalization of FVIIa and/or TF and whether TFPI⅐Xa affects the internalization of TF⅐FVIIa complexes in human fibroblasts. Our studies show that FVIIa bound to cell surface TF was internalized and degraded without depleting TF on cell surfaces. Tissue factor-specific internalization and degradation of FVIIa was significantly increased in the presence of TFPI⅐Xa complexes. In contrast to FVIIa internalization in the absence of TFPI⅐Xa, FVIIa inter-nalization in the presence of TFPI⅐Xa was associated with down-regulation of TF expression on cell surfaces. Our data also provide suggestive evidence that FVIIa complexed with TF was endocytosed by two different pathways: LRP-independent pathway in the absence of TFPI⅐Xa and LRP-dependent pathway in the presence of TFPI⅐Xa.
EXPERIMENTAL PROCEDURES
Cell Culture-A human fibroblast cell line, WI-38, was obtained from American Type Culture Collection. The cell line was grown in T-75 flasks and subcultured into 12-well tissue culture plates as described (11) . When cells reached confluency, the monolayers were washed once with buffer A (10 mM Hepes, pH 7.5, containing 150 mM NaCl, 4 mM KCl, and 11 mM glucose) containing 5 mM EDTA and then twice with the buffer A not containing EDTA before the monolayers were used in experiments.
Proteins-Recombinant human FVIIa was isolated as described (12) . FFR-FVIIa was prepared by incubating recombinant human FVIIa with a peptidyl inhibitor, D-Phe-L-Phe-L-Arg chloromethyl ketone, as described earlier (13) . Recombinant full-length TFPI and C-terminally truncated TFPI (TFPI ) expressed in baby hamster kidney cells and TFPI lacking the third Kunitz-type domain, TFPI , expressed in yeast, were gifts from Novo-Nordisk. Recombinant full-length TFPI expressed in Escherichia coli was a generous gift from Dr. Alba Creasy (Chiron Corp.). In initial experiments, we used recombinant TFPI expressed in baby hamster kidney cells. Because of the limited availability of this reagent, the majority of the experiments were carried out using recombinant TFPI expressed in E. coli. No apparent differences were found between full-length TFPI expressed in eukaryotic cells and bacteria in their effects on FVIIa binding, internalization, and degradation. Factors X (14) and Xa (15) were prepared as described previously or obtained from Enzyme Research Laboratories. Preparation of monospecific, polyclonal rabbit anti-human TF IgG was described earlier (16) . Monoclonal antibodies against human TF (TF9 -10H10) were provided by Dr. Wolfram Ruf (Scripps Research Institute, La Jolla, CA). The 39-kDa receptor-associated protein (RAP) and the affinity purified anti-LRP antibodies were generous gift of Dr. Dudley Strickland (American Red Cross, Rockville, MD).
Radiolabeling of Proteins-FVIIa, FFR-FVIIa, and TF mAb were labeled by using Iodo-Gen coated tubes and Na 125 I according to the manufacturer's technical bulletin and as described previously (17) . The labeling reaction was performed in Iodo-Gen (10 g)-coated tubes for 4 min on ice. The reaction was quenched by the addition of KI (1%), and free iodine was removed by extensive dialysis against 10 mM Hepes, pH 7.5, 150 mM NaCl. The concentration of the labeled proteins was determined by A 280 measurements. Specific radioactivity of labeled proteins was 5-9 ϫ 10 9 cpm/mg. SDS-polyacrylamide gel electrophoresis showed that the radiolabeled proteins were intact with no apparent degradation.
125
I-labeled FVIIa retained 80% or more of the functional activity of the unlabeled FVIIa.
TF-dependent Ligand Binding, Internalization, and Degradation Assays-To determine FVIIa and FFR-FVIIa binding to cell surface TF, confluent monolayers of WI-38 in 12-well culture plates were incubated with 0.5 ml of 125 I-labeled FVIIa or 125 I-labeled FFR-FVIIa (10 nM) in buffer B (buffer A containing 5 mM CaCl 2 and 1 mg/ml bovine serum albumin) for varying time periods either at 37 or 4°C. At selected times, unbound 125 I-VIIa was removed, and the monolayers were washed four times with ice-cold buffer B. The cell surface-associated radioactivity was eluted by incubating the washed monolayers for 1 min with 0.5 ml of 0.1 M glycine, pH 2.4, and the eluate was counted in a ␥ counter (Cobra, Packard Instrument Co). After eluting the cell surface-associated radioactivity, the cells were removed from the well by trypsin digestion and counted for the radioactivity to determine internalized ligand. To determine degradation of the ligand, monolayers were incubated with 125 I-labeled FVIIa or FFR-FVIIa (10 nM) as described above, and at selected time intervals an aliquot from the overlying medium was removed and precipitated with equal volume of trichloroacetic acid (20% v/v). Radioactivity associated with trichloroacetic acid-soluble fraction was taken as degraded ligand. To determine TF-specific binding, internalization and degradation of FVIIa, parallel experiments were carried out in which the monolayers were first incubated for 30 min with rabbit anti-human TF IgG (100 g/ml) before radioactive ligands were added to cells. TF-specific binding, internalization, and degradation were determined by subtracting the values from the corresponding values obtained in the absence of anti-TF antibody. In general, TF-specific binding, internalization, and degradation of 125 Ilabeled FVIIa in WI-38 cells was in the range of 70 -80%. Duplicate wells were used for all measurements, and most of the experiments were repeated 3-4 times. The data shown in the figures represent the means Ϯ S.E.
Determination of Cell Surface TF-To investigate whether TF receptors are depleted from the cell surface in the process of FVIIa internalization, monolayers were incubated at 37°C with unlabeled FVIIa and FFR-FVIIa in the presence and absence of TFPI⅐Xa for varying time periods and then chilled on ice. Cell surface TF was measured in two ways: (i) The monolayers were incubated at 4°C for 2 h with 125 Ilabeled TF monoclonal antibodies (TF9-H10) that bind to TF whether or not the TF was occupied by FVIIa. After 2 h, unbound radiolabeled TF antibodies were removed from the cells, and the cells were washed four times with ice cold buffer B. Cell-associated radioactivity was determined by detaching the cells from the wells with trypsin/EDTA digestion and counting them in a gamma counter. (ii) The monolayers were washed for 3 min with glycine, pH 2.4, to dissociate ligands associated with the cell surface, and then monolayers were washed three times with buffer B. The cell surface TF activity was assayed in a factor Xa generation assay after the addition of fresh FVIIa (10 nM) and FX (175 nM) (17) .
RESULTS
Tissue Factor-dependent Internalization and Degradation of FVIIa Bound to Fibroblasts-To determine the fate of FVIIa bound to cell surface TF, confluent monolayers of human embryonal lung fibroblasts (WI-38), which constitutively express TF, were incubated with 125 I-labeled FVIIa or 125 I-labeled FFR-FVIIa (10 nM), in the absence and presence of anti-TF IgG, for varying time periods at 37°C, and the levels of cell surfaceassociated, internalized, and degraded FVIIa were measured. As shown in Fig. 1A , FVIIa and FFR-FVIIa bound to cell surface TF in a time-dependent manner, and the saturation of cell surface binding of FVIIa occurs within 60 min. The data also show that no marked differences exist between the kinetics of FVIIa and FFR-FVIIa binding to cell surface TF. However, it should be noted that in a majority of experiments, we found 10 -20% more FFR-FVIIa associated with the cell surface as compared with FVIIa. The greater amounts of FFR-FVIIa association with cell surface TF than FVIIa could be the result of a known higher affinity of FFR-FVIIa than FVIIa to TF (13, 18) . Binding experiments performed at 4°C showed a similar amount of FVIIa binding to the cell surface but required about 120 min of incubation to reach the maximal binding (data not shown).
As shown in Fig. 1B , FVIIa and FFR-FVIIa bound to cell surface TF was internalized in a time-dependent manner, and no differences were found between FVIIa and FFR-FVIIa in their internalization. The amount of FVIIa internalized was progressively increased up to 60 min and thereafter reached steady-state levels. At the end of the 2-h incubation period at 37°C, about 20% of FVIIa associated with cells was in internalized form. As expected, no internalization of 125 I-labeled FVIIa was observed if the cells were incubated with radiolabeled FVIIa at 4°C (data not shown).
As shown in Fig. 1C , TF-mediated internalized FVIIa and FFR-FVIIa were degraded and secreted into overlying medium. No differences were found between FVIIa and FFR-FVIIa in their degradation. The rate of degradation was linear after 1 h of incubation, and about 150 fmol of FVII/10 6 cells were degraded per hour.
Effect of TFPI⅐Xa on the Binding, Internalization, and Degradation of FVIIa-To test whether the binding of plasma inhibitor TFPI to cell surface TF⅐FVIIa complexes affects the kinetics of FVIIa binding, internalization, and degradation, WI-38 cells were incubated with 125 I-labeled FVIIa (10 nM) in the presence of TFPI⅐Xa complexes (10 nM). The data show that TFPI⅐Xa markedly enhanced the internalization of FVIIa bound to cell surface TF (Fig. 2B) . TFPI⅐Xa-induced increase in internalization of FVIIa was associated with an increased degradation of FVIIa (Fig. 2C) . TFPI⅐Xa also slightly enhanced the amount of FVIIa associated with the cell surface TF ( Fig. 2A) , and this could be due to a slower dissociation of FVIIa from the quaternary complex of TF⅐FVIIa⅐TFPI⅐Xa (19) . TFPI⅐Xa had no effect on the cellular uptake and degradation of FFR-FVIIa (Fig. 2) .
Next, we investigated structural requirements of TFPI for its ability to increase the rate of FVIIa internalization. Preincubation of cells with anti TFPI-IgG did not prevent the base level of FVIIa internalization, which indicates that traces of endogenous TFPI that could be possibly present on cell surfaces is not responsible for the internalization of FVIIa observed in the absence of exogenously added inhibitor. TFPI had to be in complex with factor Xa to increase the cellular uptake of FVIIa, because TFPI and factor Xa alone had no significant effect on the internalization of FVIIa (Fig. 3A) . To examine the role of C-terminal region and the third Kunitz domain of TFPI in TF-mediated internalization of FVIIa, we have used recombinant TFPI variants, TFPI lacking C-terminal region (TFPI and TFPI lacking both the third Kunitz domain and Cterminal region (TFPI ). As shown in Fig. 3B , unlike TFPI⅐Xa, TFPI 1-250 ⅐Xa, and TFPI 1-161 ⅐Xa complexes only minimally enhanced the extent of FVIIa internalization, indicating that intact C terminus of TFPI is required for enhancing the internalization of FVIIa bound to TF.
We also examined the effect of full-length TFPI⅐Xa and truncated variant TFPI⅐Xa complexes on their ability to inhibit cell surface TF⅐FVIIa functional activity (measured in factor X
FIG. 1. TF-specific binding, internalization and degradation of FVIIa and FFR-FVIIa in fibroblasts.
125 I-labeled FVIIa (E) or 125 Ilabeled FFR-FVIIa (q) (10 nM each) added to confluent monolayers of WI-38 cells that were preincubated for 30 min at 37°C with a control buffer or the buffer supplemented with polyclonal rabbit anti-human TF IgG (100 g/ml). At varying time periods, the unbound radiolabeled ligand was removed, and cell surface-associated, internalized, and degraded radioligand was determined as described under "Experimental Procedures." The data shown in the figure represent TF-specific binding (A), internalization (B), and degradation (C). TF-specific binding, internalization, and degradation were determined as the difference between total binding, internalization, and degradation (obtained in the absence of anti-TF IgG) and nonspecific binding, internalization, and degradation (obtained in the presence of anti-human TF IgG). Data shown are the means Ϯ S.E. (n ϭ 3). activation assay). All TFPI⅐Xa preparations at a 10 nM concentration completely inhibited TF⅐FVIIa functional activity, and no significant differences were found in their inhibitory activity.
Heparin Reduces TFPI⅐Xa-enhanced Internalization and Degradation of FVIIa-Because the basic C terminus of TFPI has been shown previously to bind heparin (20) and because the above experiments show C-terminal region of TFPI is important for TFPI⅐Xa-enhanced internalization and degradation of FVIIa, we have examined the ability of heparin to affect FVIIa binding, internalization, and degradation in the presence and absence of TFPI⅐Xa. As shown in Fig. 4 , heparin had no significant effect on FVIIa internalization and the subsequent degradation in the absence of TFPI⅐Xa. However, heparin reduced TFPI⅐Xa-enhanced internalization by 30% and the degradation by about 50%. The decreased internalization and degradation of FVIIa by heparin did not stem from the impairment in FVIIa binding to cell surfaces because the same amount of FVIIa was associated with cell surface TF in the presence and absence of heparin (data not shown).
RAP and Anti-LRP Antibodies Inhibit Internalization and Degradation of FVIIa in the Presence TFPI⅐Xa but Not in Its
Absence-TFPI was shown to bind directly to LRP (21) , and LRP mediates the cellular uptake and degradation of TFPI (22) . Further, LRP functions as an endocytosis receptor for a number of diverse ligands that are involved in lipoprotein metabolism and coagulation regulation (23) . Therefore, we examined the role of LRP in FVIIa uptake and degradation by using anti-LRP antibodies and RAP, a 39-kDa protein that inhibits the binding and/or cellular uptake of all ligands by LRP (23) . Anti-LRP antibodies and RAP had no or only minimal effect on the internalization and degradation of FVIIa in the absence of TFPI⅐Xa (Fig. 5) . In contrast, both anti-LRP antibodies and RAP inhibited TFPI⅐Xa-increased internalization and degradation of FVIIa (Fig. 5) . The effect of anti-LRP antibodies and RAP was more pronounced in TFPI⅐Xa-mediated degradation of FVIIa (60 -90% inhibition) than TFPI⅐Xa-mediated internalization (30 -60% inhibition). Both anti-LRP antibodies and RAP had no significant effect on FVIIa binding to cell surface TF in the absence and presence of TFPI⅐Xa. In fact, RAP slightly enhanced the amount of FVIIa associated with cell surface TF (data not shown).
Effect of Acidification on FVIIa Internalization and Degradation-The above data that show heparin and RAP inhibit the internalization and degradation of FVIIa in the presence of TFPI⅐Xa but not in its absence, suggest that FVIIa⅐TF and FVIIa⅐TF⅐TFPI⅐Xa complexes are internalized via different endocytotic pathways. To examine the role of coated pits on FVIIa internalization and degradation, we have depleted coated pits on cell surface by cytosol acidification. As shown in Fig. 6 , acidification of cells did not affect FVIIa binding to cell surface TF in the presence and absence of TFPI⅐Xa. In the presence of TFPI⅐Xa, acidification inhibited FVIIa internalization by more than 50% and the degradation by 80%. In contrast, acidification had a minimal effect on the internalization and degradation of FVIIa not complexed with TFPI⅐Xa (Fig. 6) .
Recycling of Internalized FVIIa-Next, we examined whether a portion of internalized FVIIa could recycle back to cell surface. In these experiments, WI-38 cells were incubated with 125 I-labeled FVIIa in the presence and absence of TFPI⅐Xa for 1 h at 37°C to allow internalization of FVIIa. Thereafter, cell surface-associated radiolabeled FVIIa was completely removed by treating the cells with low pH buffer, and the monolayers were allowed to stand at 37°C. At the end of 30-and 90-min incubation periods, the amount of cell surface-associated, degraded, and internalized FVIIa were determined as described under "Experimental Procedures." As shown in Fig.  7 , at the end of 30 min, although the majority of FVIIa remain inside the cell, a significant portion of internalized FVIIa (about 25%) was associated with the outer cell surface. We also observed recycling of FVIIa, to a lower extent (about 15%), that was internalized with TFPI⅐Xa. Furthermore, a small portion of secreted radioactivity in the overlying medium could be precipitable with 10% (v/v) trichloroacetic acid, suggesting the release of intact FVIIa from the internalized pool. This was further supported by SDS-polyacrylamide gel electrophoresis analysis, which showed that trichloroacetic acid-precipitable FVIIa migrated as a single band with approximate molecular mass of 50 kDa (Fig. 7B) . At the end of 90 min, the fraction of cell surface-associated FVIIa remained unchanged or slightly reduced, but the amount of internalized FVIIa was decreased substantially with a corresponding increase in the secretion of degraded FVIIa (data not shown).
To obtain further support for the observation that a portion of internalized FVIIa recycles back to the cell surface, we have monitored the expression of TF⅐FVIIa functional activity. In these experiments, unlabeled FVIIa was allowed to internalize as described above. After the removal of cell surface-associated FVIIa, the cells were allowed to stand at 37°C for varying time periods before adding factor X to determine TF⅐FVIIa functional activity. Because no FVIIa was added with factor X, the rate of factor X activation directly correlates to the amount of FVIIa recycled onto the cell surface TF. As shown in Fig. 7B , factor X activation was increased in a time-dependent manner for 30 min, indicating the appearance of functionally active FVIIa on the cell surface. (A low level of factor X activation seen at zero time could possibly be due to the presence of trace contaminant FVII in the factor X preparation.) When similar experiments were carried out to evaluate the recycling of FVIIa that was internalized with TFPI⅐Xa, we found that factor X was activated with a rate less than 20% of that was obtained with FVIIa internalized in the absence of TFPI⅐Xa (data not shown). This could be due to a combination of a lower extent of FVIIa recycling that was internalized with TFPI⅐Xa and/or possible recycling of TFPI⅐Xa that could inhibit the functional activity of recycled FVIIa.
Internalization of TF-
The above experiments clearly establish that FVIIa bound to TF is internalized and TFPI⅐Xa enhances the extent of FVIIa internalization. However, these data do not provide any information on the fate of cell surface TF. To examine this, we have monitored the expression of cell surface TF in cells exposed to a variety of experimental conditions by determining the radiolabeled TF mAb binding to cells and also by measuring the expression of cell surface TF functional activity. For binding studies, we chose a TF mAb, TF9 10H10, because it was shown to bind to TF at an epitope that was not affected by FVIIa and factor X binding to TF (24) . Further, Western blot analysis using whole cell extract of WI-38 cells established that the antibody recognized a single protein, corresponding to the molecular mass of purified human brain TF (45 kDa).
In initial experiments, we characterized TF mAb binding to WI-38 cells by incubating monolayers with varying concentrations of 125 I-labeled TF mAb at 4°C in the presence and absence of 100-fold molar excess of unlabeled antibody. The data show that TF mAb bound to cell surface TF in a dose-dependent and saturable manner with a high specificity. The amount of nonspecific binding of TF mAb to the cell surface was negligible (less than 5%) (Fig. 8A) . A 10 -20 nM concentration of TF mAb was sufficient to obtain saturable binding. As expected, the binding of TF mAb to cell surface TF was not affected by the presence of FVIIa or FVIIa and TFPI⅐Xa (data not shown). The apparent discrepancy in the amount of TF mAb and FVIIa bound to cell surface TF (Figs. 1A and 8A ) could be the result of variation in TF expression in different batches of cells used in these experiments. Additional experiments were carried out to examine whether TF mAb bound to cell surface TF was internalized. As shown in Fig. 8B , the cell-bound TF mAb was internalized at 37°C in a time-dependent manner, and the rate of internalization was about 400 fmol/10 6 cells/h. To determine whether internalization of TF mAb was associated with depletion of cell surface TF, we first incubated the monolayers with unlabeled TF mAb at 37°C for various time periods and then measured the amount of cell surface TF by radiolabeled FVIIa binding and functional activity assay. The preincubation of cells with TF mAb resulted in a minimal decrease in the subsequent FVIIa binding to cell surface TF (Fig. 9A ) and no change in the functional expression of cell surface TF (Fig. 9B ). These data demonstrate that internalization of TF mAb was not associated with depletion of TF recep- tors on the cell surface, suggesting a rapid recycling of internalized TF receptor. Although with the present data we cannot rule out the possibility that the antibody binding to TF induced the internalization of TF, the data are also compatible with the hypothesis that TF receptor is continuously internalized and recycled in the absence of the ligand.
To investigate whether TF receptors were depleted from the cell surface in the process of FVIIa internalization, monolayers of WI-38 cells were incubated at 37°C for 2 h with unlabeled FVIIa or FFR-FVIIa in the presence and absence of plasma inhibitors. Then the monolayers were chilled on ice and incubated with 125 I-labeled TF mAb (10 nM) for 2 h at 4°C to determine TF levels on the cell surface. As shown in Fig. 10 , a significant decrease in TF mAb binding was observed in cells that were pretreated with FVIIa and TFPI⅐Xa. These data indicate that TFPI⅐Xa binding to TF⅐FVIIa resulted in the depletion of cell surface TF. It is important to point out here that a decrease in 125 I-labeled TF mAb binding was observed only when the cells were preincubated with FVIIa, TFPI⅐Xa at 37°C but not at 4°C (data not shown). This rules out that steric hindrance for TF epitope recognized by the TF mAb as a cause for the above observation. Unlike TFPI⅐Xa, other plasma inhibitors of TF⅐FVIIa, i.e., antithrombin/heparin, failed to deplete TF from the cell surface. The data also show that exposure of cells to FFR-FVIIa in the presence and absence of TFPI⅐Xa did not deplete cell surface TF.
TFPI⅐Xa-induced internalization of TF was also evident in a functional assay. As shown in Fig. 11A , incubation of cells for
FIG. 7. Recycling of internalized FVIIa. A,
125 I-labeled FVIIa (10 nM) Ϯ TFPI⅐Xa (10 nM) added to WI-38 cells. After 1 h incubation at 37°C, the unbound ligands were removed, cells were washed, and the cell surface-associated ligands were eluted with 0.1 M glycine, pH 2.4, treatment. Immediately after the glycine treatment, the monolayers were washed three times with buffer B and allowed to stand at 37°C. At the end of 30 min, overlying buffer (contains dissociated/degraded FVIIa) was removed, and the monolayers were washed with low pH buffer to elute cell surface-associated radioligand. Thereafter, cells (containing internalized FVIIa) were removed from the plate by trypsin digestion. All fractions were counted for radioactivity. The fraction of FVIIa precipitable with 10% trichloroacetic acid in the overlying medium was considered as intact FVIIa. Dotted bars represent recycling of FVIIa internalized in the absence of TFPI⅐Xa, and hatched bars represent recycling of FVIIa internalized as FVIIa⅐TF⅐TFPI⅐Xa complexes. The data from a representative experiment are shown (n ϭ 3). B, WI-38 cells were incubated with 125 I-labeled FVIIa (10 nM) for 60 min 37°C. At the end of incubation, the monolayers were washed with low pH buffer to remove cell surface-associated 125 I-labeled FVIIa and overlaid with fresh buffer B as described for A. At the end of 5 or 90 min, the overlying buffer was removed and precipitated with 10% trichloroacetic acid. Both trichloroacetic acid precipitates and the cells were solubilized in SDS-polyacrylamide gel electrophoresis buffer and subjected to SDSpolyacrylamide gel electrophoresis followed by autoradiography. I-labeled FVIIa. After removing the unbound and the cell surface-associated FVIIa, the monolayers were allowed to stand at 37°C. After varying time periods, FX (100 nM) was added to cells, and the amount of Xa generated after a 5-min activation period was determined. The data were normalized relative to maximal TF⅐FVIIa activity that was obtained by adding 10 nM FVIIa with FX. Data shown are the means Ϯ S.E. (n ϭ 4) .
FIG. 8. Binding and internalization of TF mAb in fibroblasts.
A, varying concentration of 125 I-labeled TF mAb (TF9 10H10), in the presence (Ⅺ) and absence (f) of 100-fold molar excess of unlabeled antibody were added to WI-38 cells. At end of 2 h of incubation at 4°C, the unbound ligand was removed, cells were washed, and the cellassociated radioactivity was counted. Specific binding of TF9 10H10 (‚) was determined by subtracting the nonspecific binding (Ⅺ) from the total binding (f). The data from a representative experiment are shown (n ϭ 3). B, WI-38 cells were incubated with 125 I-labeled TF mAb (10 nM) for 2 h at 4°C to allow the antibody binding to cells and then warmed to 37°C for various time periods. The unbound radioligand was removed, cell surface-associated radioactivity was eluted by treating the cells with low pH glycine, and the remaining cell-associated radioactivity was counted. Data shown are the means Ϯ S.E. (n ϭ 4).
2 h at 37°C with FVIIa and TFPI⅐Xa reduced the functional expression of cell surface TF activity by 40%. The levels of cell surface TF could be further depleted upon prolonged incubation with FVIIa and TFPI⅐Xa (Fig. 11B) . Similar reduction in TF was also observed in cells that were pretreated with cycloheximide (10 g/ml) to inhibit new protein synthesis or serum starved for 24 h to deplete TF mRNA before they were exposed to FVIIa and TFPI⅐Xa (data not shown).
DISCUSSION
Vascular injury leads to the exposure of blood to fibroblasts and smooth muscle cells within the vessel wall. Fibroblasts constitutively express cell surface TF, a cellular receptor for plasma clotting factor VII(a). In general, the binding of ligand to receptor is accompanied by endocytosis of the ligand-receptor complex and by replenishment of free membrane receptors. Many serine proteinases that participate in blood coagulation, fibrinolysis, and inflammation are rapidly removed from circulation once they bind to their cellular receptor and thus regulate their biological activity (25) . For example, internalization of thrombin-thrombomodulin complexes had been proposed as a mechanism for clearing thrombin from the circulation and preventing excessive protein C activation (26, 27) . Such receptor-mediated endocytosis could play an important role in the regulation of TF-dependent coagulation, but as of yet, not much information is available on the fate of FVIIa⅐TF complexes formed on cell surfaces.
In the present study, we found that FVIIa bound to TF in fibroblasts was internalized and subsequently degraded in a time-dependent manner. The addition of plasma inhibitor complex, TFPI⅐Xa, enhanced the internalization of FVIIa bound to TF by about 3-fold. TFPI⅐Xa also slightly increased the number of FVIIa molecules associated with TF, presumably by tightening the FVIIa binding to TF by forming the FVIIa⅐TF⅐TFPI⅐Xa quaternary complex (19) . However, this alone cannot account for the enhanced internalization of FVIIa observed in the presence of TFPI⅐Xa. Active-site inactivated FVIIa, FFR-FVIIa, bound to TF was internalized and degraded with kinetics similar to FVIIa. These data suggest that active-site modification does not affect the internalization of FVIIa. In this context, it may be important to point out that FFR-FVIIa was shown to bind to cell surface TF with the same or higher affinity than FVIIa (18) . In contrast to FVIIa, FFR-FVIIa internalization and degradation was not influenced by the presence of TFPI⅐Xa. This is an expected finding because the active site of FVIIa was required for TFPI⅐Xa to interact with FVIIa⅐TF complexes.
TFPI-induced internalization of FVIIa requires the formation of a quaternary complex of FVIIa⅐TF⅐TFPI⅐Xa because TFPI in the absence of Xa failed to increase the internalization of FVIIa. The C-terminal domain of TFPI appears to play a critical role in TFPI⅐Xa-induced internalization of FVIIa because the truncated forms of TFPI failed to enhance the internalization of FVIIa even though they could effectively inhibit the functional activity of cell surface FVIIa⅐TF complexes.
It is interesting to note that although substantial amounts of FVIIa complexed with TF were internalized even in the absence of TFPI⅐Xa, presumably as FVIIa⅐TF complexes, this internalization of FVIIa was not associated with down-regulation of TF expression on cell surfaces. Even prolonged incubation of FVIIa with cells in the presence of protein synthesis inhibitor cycloheximide failed to deplete the expression of TF on cell surfaces. These data suggest that the internalized TF rapidly recycles back to the cell surface. This assumption was further supported indirectly by TF mAb internalization studies. Our data clearly document that TF mAb bound to TF was rapidly internalized without depleting TF on cell surfaces. At present, it is not clear whether FVIIa or TF mAb bound to TF were internalized because they specifically induce internalization of TF or because of constitutive internalization/recycling of TF. Experiments performed to test these possibilities were not fruitful because we were unable to fully remove TF receptor from the cell surface by protease treatments (such as trypsin, chymotrypsin, subtilisin, and Pronase), which is an essential step in evaluating the constitutive internalization of the receptor using standard procedures (28, 29) . Similarly, use of cleavable biotinylation of cell surface receptors and monitoring TF by either immunoprecipitation and/or enzyme-linked immunosorbent assays were met with technical difficulties. Thus, in the absence of specific and direct evidence for TF internalization and recycling, we cannot entirely rule out the possibility that FVIIa or FVIIa⅐TFPI⅐Xa is internalized by a mechanism that does not involve TF internalization.
In contrast to FVIIa internalization in the absence of TFPI⅐Xa, TFPI⅐Xa-induced internalization of FVIIa was associated with the down-regulation of TF expression on cell surfaces. These data are consistent with the recent observations of Hamik et al. (10) . These investigators showed that culturing monocytic cells in the presence of both FVIIa and TFPI caused down-regulation of TF expression. However, a major difference exists between our data and the earlier data. Hamik et al. (10) reported that TFPI-mediated down-regulation of TF expression was independent of Xa and that the formation of trimolecular complex FVIIa⅐TF⅐TFPI was sufficient to down-regulate the TF expression in monocytes. However, in the present studies with fibroblasts, we found that TFPI-mediated down-regulation of TF requires the presence of Xa. This difference could be the result of the use of different cell model systems in these experiments and/or different methodologies used to monitor the expression of TF. Whereas in the presented study, we evaluated the TF expression on intact cell surfaces using functional assays and mAb binding studies, Hamik et al. (10) monitored TF expression by measuring TF antigen in cell lysates.
Differences in TF down-regulation when it is complexed with the free ligand (FVIIa or mAb) or with the ligand plus the inhibitor (FVIIa, TFPI⅐Xa) suggest that TF internalized in complex with FVIIa⅐TFPI⅐Xa was trafficked through a different intracellular route than TF internalized with FVIIa or with mAb. In the case of FVIIa⅐TF complexes, it is likely that internalized complexes delivered to early (sorting) endosomes are dissociated and TF enters into the recycling compartment to shuttle back to the cell surface, whereas FVIIa enters late endosomes and is subsequently degraded in lysosomes. In case of FVIIa⅐TF⅐TFPI⅐Xa complexes, the internalized complexes delivered into early endosomes enter into late endosomes and then to lysosomes for degradation of all components of the complex. The stability of internalized complexes may play a role whether TF recycles back to the cell surface or directed to degradation pathways. For example, FVIIa⅐TF complexes readily dissociate, whereas FVIIa⅐TF⅐TFPI⅐Xa complexes are much more stable (19) , and thus the complexes may enter into late endosomes before they dissociate. It is possible that participation of other cellular components in the internalization process could also dictate the fate of the internalized complex.
TFPI, in addition to binding to cell surface FVIIa⅐TF complexes, also binds specifically to cell surfaces via LRP and heparan sulfated proteoglycans (HSPG) (21, 30, 31) . Heparin, which competes with TFPI for binding to HSPGs (32, 33) , inhibited TFPI⅐Xa-mediated internalization and degradation of FVIIa. Similarly, anti-LRP antibodies and RAP, which blocks binding of TFPI and other ligands to LRP (23), also inhibited TFPI⅐Xa-mediated internalization and degradation of FVIIa. The effect of anti-LRP antibodies and RAP was more pronounced compared with heparin in inhibiting TFPI⅐Xa-induced internalization and degradation of FVIIa. These data suggest that LRP plays an essential role in TFPI⅐Xa-induced internalization of FVIIa. TFPI interaction with HSPGs may also contribute to the process. Involvement of LRP in TFPI⅐Xa-mediated internalization and degradation of FVIIa is consistent with the earlier observation that LRP plays an essential role in TF down-regulation in monocytes that are exposed to FVIIa and TFPI (10) . However, in monocytes the down-regulation of TF by TFPI does not appear to be dependent upon TFPI interaction with HSPGs (10). It is likely that the monocytic cells may not have possessed appropriate HSPGs that could interact with TFPI.
It has been proposed that LRP directs the FVIIa⅐TF⅐TFPI and FVIIa⅐TF⅐TFPI⅐Xa complexes to clathrin coated pits where the complex can be internalized (10) . Our data that show acidification of WI-38 cells markedly decreases the internalization of FVIIa complexed with TF⅐TFPI⅐Xa supports the above hypothesis. Acidification of the cytosol in a number of cell lines was shown to selectively inhibit endocytotic pathway via coated pits by changing the clathrin lattice morphology and inhibiting the pinching off of coated pits (34, 35) . In contrast to FVIIa in the inhibited complex, acidification of cells did not affect the internalization of FVIIa complexed with TF in the absence of TFPI⅐Xa.
Overall, our data are compatible with a notion that FVIIa bound to cell surface TF was endocytosed by two different pathways. FVIIa bound to TF in the absence of TFPI⅐Xa was internalized via LRP-independent and probably through a noncoated pit-mediated pathway, whereas FVIIa complexed with TF⅐TFPI⅐Xa was internalized via LRP-dependent coated pit pathway. Although most of the internalized FVIIa, irrespective of which pathway it was internalized, was degraded, a small portion of internalized FVIIa is recycled. Our findings also provide indirect evidence that TF internalized as FVIIa⅐TF complexes rapidly recycles back to the cell surface, whereas most of the TF internalized as FVIIa⅐TF⅐TFPI⅐Xa complexes was not recycled. However, it is likely, as with FVIIa, that a small portion of TF internalized as FVIIa⅐TF⅐TFPI⅐Xa complexes recycles back to the cell surface because even the prolonged incubation of cells with FVIIa and TFPI⅐Xa failed to deplete the cell surface TF expression completely. In summary, our data suggest that TFPI⅐Xa-mediated internalization and degradation of both FVIIa and TF provide an additional mechanism for down-regulation TF⅐FVIIa functional expression on cell surfaces.
